BDX Overview

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is192.64 USD with a low forecast of 157.00 USD and a high forecast of 232.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Becton Dickinson and Co revenue for the last quarter amounts to 4.71B USD, increased 5.22

Becton Dickinson and Co. EPS for the last quarter amounts to -1.11 USD, decreased -203.74

Becton Dickinson and Co (BDX) has 72000 emplpoyees as of May 11 2026.

Today BDX has the market capitalization of 41.17B USD.